Compass Pathways' COMP360 Data Supports FDA Approval Potential, RBC Says
() -- Compass Pathways' (CMPS) recent six-month trial data for COMP360 in treatment-resistant depression supports its potential for US Food and Drug Administration approval, a 2027 launch, and a more than $1.7 billion market opportunity, RBC Capital Markets said in a note Tuesday. The analysts said the data showed a me